Dedifferentiated parosteal osteosarcoma of the maxilla: a case report and review of the literature

Hidetaka Miyashita, Kazunari Yoshida, Tomoya Soma, Kaori Kameyama, Aya Sasaki, Masanori Hisaoka, Masaki Yazawa, Hideo Morioka, Moe Takahashi, Taneaki Nakagawa and Hiromasa Kawana

Abstract

Background: Parosteal osteosarcomas are usually low-grade tumors, however, sometimes they transform to high-grade tumors, which is named dedifferentiation. This phenomenon has been reported in long bones. Recently, we encountered a patient with dedifferentiated parosteal osteosarcoma occurring in the maxilla. Here, we report a first case of dedifferentiated parosteal osteosarcoma of the head and neck region.

Case presentation: A 45-year-old Japanese woman with a refractory bone lesion in the maxilla presented to our hospital. A biopsy showed atypical spindle cell proliferation involving dedifferentiated high-grade component, which was diagnosed as dedifferentiated parosteal osteosarcoma. Three cycles of neoadjuvant chemotherapy using ifosfamide and pirarubicin were performed followed by sub-total maxillectomy. Histopathological results showed that neoadjuvant chemotherapy was effective for high-grade component. The decision to perform adjuvant chemotherapy (cisplatin and pirarubicin) was made because distant metastasis has been reported, even in cases with dedifferentiated parosteal osteosarcoma in which complete necrosis of high-grade component was achieved due to neoadjuvant chemotherapy. There was no recurrence 15 months after surgery.

Conclusions: Dedifferentiated parosteal osteosarcoma can occur in the head and neck region. Chemotherapy including anthracycline anticancer agent could be effective for high-grade component of dedifferentiated parosteal osteosarcoma.

Keywords: Parosteal osteosarcoma, Dedifferentiated, Maxilla, Head and neck, Chemotherapy, Case report

Background

Dedifferentiated parosteal osteosarcoma (DPOS) is defined as a high-grade surface osteosarcoma which rarely occurs as either a primary or secondary event of conventional low-grade parosteal osteosarcoma (c-POS) [1]. Several incidences of dedifferentiation in c-POS were reported by earlier studies (18–24%) [1–3]. c-POS is known to have a good prognosis after local excision. However, DPOS has the ability to metastasize systemically, which results in an uncontrollable condition [4]. Although many treatment strategies have been attempted, definite evidence-based treatment has not yet been established due to a low incidence rate of DPOS. DPOS mainly arises from long bones such as femur, humerus, and tibia [3]. However, to the best of our knowledge, cases of DPOS arising from the head and neck region have not been reported so far. Here, we present a case of DPOS of the maxilla treated with combination therapy, including surgery and chemotherapy. Furthermore, we review the available literature and we discuss treatment strategies with a focus on chemotherapy.
**Case presentation**

A 45-year-old Japanese woman with a swelling and bone exposure of the left buccal region was referred to our hospital. She had previously undergone excisional biopsy two times, which led to the same diagnosis of osteoma. She had no special medical and family history. On clinical examination, maxillary bone exposure without pain was observed around her upper left second molar. Other physical status was normal. Computed tomography (CT) showed a diffuse radiopaque lesion around the alveolar cortical bone surface of her maxilla spanning from the first molar to the second molar (Fig. 1). A biopsy demonstrated features of necrotic bone without atypia. The exposed region in her maxilla recovered with healthy oral mucosa naturally after the biopsy without any additional treatment. However, she noticed bone exposure again in the same region after a year and swelling that tended to enlarge over time. As she did not want to undergo radical surgery requiring tooth extraction, we performed debulking surgery including biopsy twice in 2 years. However, these biopsies did not demonstrate features of malignancy. The lesion enlarged gradually during the observation period and CT showed a diffuse bone mass accompanied by radiolucent areas, which arose from the surface of maxillary alveolar bone and invaded into the pterygopalatine fossa (Fig. 2).

T1-weighted fat-suppressed magnetic resonance imaging (MRI) after injection of intravenously administered contrast medium showed heterogeneous contrast-enhanced masses and hypointense areas corresponding to mineralized areas on CT (Fig. 3). Histopathological assessment showed stromal component consisting of dense atypical spindle cell proliferation and focal cartilage formation with mild atypia (Fig. 4). Immunohistochemical staining showed diffuse expression of β-catenin and α-smooth muscle actin (α-SMA) in atypical spindle cells. These cells were also stained by runt-related gene 2 (RUNX-2), special AT-rich sequence-binding protein 2 (SATB2), or sex-determining region Y-box 9 (SOX9), indicating that these cells were derived from cells that had the ability to differentiate into osteoblastic cells and cartilage cells (Fig. 5). Moreover, co-expression of murine double minute 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) along with a dedifferentiated subtype of high-grade sarcoma was seen [5]. We excluded a diagnosis of chondrosarcoma and high-grade osteosarcoma because these histopathological features are usually negative in these conditions. Together with these findings, we arrived at a diagnosis of DPOS derived from c-POS. Indication of distant metastasis was not documented. Finally, we diagnosed this patient as stage IIB DPOS based on Enneking staging system [6].

The condition was treated by wide resection and chemotherapy. Since evidence-based chemotherapy for DPOS has not yet been established, we performed neoadjuvant chemotherapy (NAC) consisting of pirarubicin (THP-ADM) and ifosfamide (IFO) based on clinical trials carried out by the Japan Clinical Oncology Group (JCOG) 0304 [7]. THP-ADM (30 mg/m², days 1 and 2) and IFO (2 g/m², days 1–5) were administered and mesna (400 mg/m²) was added at 4 and 8 hours after infusion of IFO. This regimen was repeated for three cycles every 3 weeks. The administration dose was decreased by 40% for the second and third cycles, because grade 4 neutropenia and grade 3 febrile neutropenia were observed in the initial cycle. Although slight shrinking of the tumor was observed in radiological examination after three cycles of chemotherapy, the majority of the tumor did not demonstrate any other changes.

Subsequently, we performed subtotal maxillectomy using combined transcranial approach with orbitozygomatic osteotomy and transcervical approach with mandibulectomy. This approach was selected to avoid permanent surgical scar on our patient’s visible mid-face. Subtotal maxillectomy from her oral cavity was followed by a skull base surgery. Following resection of the lateral wall of the orbit, orbitozygomatic osteotomy was performed, which was contiguous to osteotomy from the oral cavity. The tumor invaded toward the foramen ovale and close to her optic nerve. We separated the tumor carefully from these anatomical structures on the upper levels of pterygopalatine fossa. Eventually,
radical resection with an adequate margin was achieved followed by reconstruction surgery. After reconstruction of the lateral wall of the orbit with a titanium mesh, raw surface muscular flap reconstruction was also carried out immediately, as described previously [8]. Since morphological reconstruction mimicking natural morphology of the palate can be achieved by using this method, it was easier to apply the dental prosthesis for our patient. Finally, the temporal bone was restored and removed zygomatic bone was restored using an absorbent plate (Fig. 6).

The surgical specimen was examined histopathologically. Although a decrease in cell density and tumor degeneration due to NAC were observed in the high-grade component, the number of tumor cells in the low-grade component remained viable. Therefore, the chemotherapy effect was considered to be grade 1 based on the Huvos grading system (grade 1, 0–49% necrosis) [9]. Based on the recommendation of adjuvant chemotherapy in DPOS treatment [4], we decided to administer additional chemotherapy using cisplatin (CDDP) + THP-ADM. Adjuvant chemotherapy consisted of CDDP (120 mg/m², day 1) and THP-ADM (30 mg/m², days 1 and 2), and was repeated for two cycles every 3 weeks. The administration dose was decreased by 40% for all cycles due to experiences of adverse effects of NAC. The post-treatment progress was good, and no severe functional morbidity, such as eating dysfunction or dysphonia, was observed. As for our patient’s quality of life (QOL), her General Oral Health Assessment Indices (GOHAI) [10] were 59 and 53 points before operation and a year after surgery, respectively (generalized mean, 53.1; Table 1). She has shown no indication of recurrence after 15 months.

Fig. 2 Computed tomography image showing heterogeneous bone mass. Feasibility of medullary bone invasion toward the inferior orbital fissure via pterygopalatine fossa

Fig. 3 Magnetic resonance imaging showing diffuse mass with the contrast effect existing mainly in the pterygopalatine fossa. The contrast-enhanced areas correspond with the radiolucent area on computed tomography
Discussion

To the best of our knowledge, this is the first report of DPOS of the head and neck region. Previous literature has reported that 18% of cases of c-POS undergo dedifferentiation and cases of DPOS comprise a high-grade spindle cell sarcoma component coexisting with a lower grade typical parosteal osteosarcoma [2]. Dedifferentiation was often observed at the time of recurrence [1], although according to the experience of the Rizzoli Institute [3], the most dedifferentiated component was present in the initial lesion (synchronous). Therefore, in the case of c-POS diagnosed by biopsy before surgery, the potential for dedifferentiation occurring in primary c-POS should be considered in the treatment plan [3]. From the above viewpoints, accurate diagnostic methods for DPOS are needed to make appropriate treatment decisions. The usefulness of gadolinium (Gd)-enhanced T1-weighted MRI for detecting the dedifferentiation has been reported [11]. However, controversy exists over the value of MRI for the diagnosis of DPOS. Donmez et al. reported that MRI signal characteristics are not useful for tumor grading [12]. The main advantage of MRI is that contrast-enhanced images may delineate the appropriate biopsy site [12]. In the present case, we may have found the dedifferentiation by taking specimens from the contrast-enhanced region. It is challenging to make a diagnosis of DPOS before treatment. Comprehensive and careful assessments are required for an accurate diagnosis of DPOS.

Wide resection is generally accepted as the main treatment strategy for DPOS. However, the clinical importance of chemotherapy associated with wide resection surgical treatment is not clear. To the best of our knowledge, there are only three articles on DPOS in which the detailed histological assessment of preoperative chemotherapy is described (Table 2) [3, 4, 11]. Although the number of cases is small, NAC, including

![Fig. 4](image)

**Fig. 4** Hematoxylin-eosin staining demonstrating the atypical spindle cells with nuclear enlargement and nucleus with irregular shape

![Fig. 5](image)

**Fig. 5** Immunohistochemical staining findings demonstrating the origin of atypical spindle cells. **a, b** Positive findings of RUNX-2 and SATB2 staining osteoblastic cell. **c** SOX-9 positive indicated by arrows suggests the origin of these spindle cells from cartilage cells
anthracycline anticancer agent, tends to be effective for DPOS. In the case presented here, we used IFO and THP-ADM for three cycles before surgery. Focusing on the high-grade component, almost all of these areas were necrotic due to the chemotherapy effect. The past literature [4], as described in Table 2, reported that the survival rate tends to be better in the group responding well to chemotherapy (with >90% necrosis of the high-grade component). Moreover, disease-free survival was prolonged significantly ($P = 0.03$) in patients with a good response (median, 75 months) compared with those who responded poorly (median, 13 months) [4]. Together with these findings, chemotherapy including anthracycline anticancer agent could be effective for high-grade component of DPOS and may contribute to disease control. On the other hand, Bertoni et al. reported that there are no differences in survival rates between patients treated only with wide resection and wide resection with chemotherapy [3]. Furthermore, although c-POS has lower potential for distant metastasis, it cannot be ruled out that patients without dedifferentiation may develop distant metastasis [1]. In addition, Takeuchi et al. reported well-differentiated metastases in patients with DPOS, consisting of only the low-grade component and exhibiting a poor response to chemotherapy, thus concluding that dedifferentiation of tumors and the development of metastasis can occur independently [13]. In the present case, the chemotherapy effect was poor except for high-grade components. Given that DPOS coexists with c-POS, the value of chemotherapy for DPOS remains unclear. Further studies with evidence-based approaches are needed before chemotherapy treatment for DPOS can be standardized.

Conclusions
A rare case of DPOS in the maxilla is presented. Our report suggests that DPOS can arise from the head and neck region and chemotherapy consisting of THP-ADM and IFO could be effective for high-grade components. Further studies are needed to establish an appropriate treatment strategy for DPOS.

Table 1 General Oral Health Assessment Index scores

| GOHAI items                              | Preoperation | A year after surgery |
|------------------------------------------|--------------|----------------------|
| 1. Limit the kinds of food               | 5            | 5                    |
| 2. Trouble biting or chewing             | 5            | 3                    |
| 3. Problems to swallow comfortably       | 5            | 5                    |
| 4. Problems to speak clearly             | 5            | 3                    |
| 5. Discomfort when eating any kind of food | 5           | 4                    |
| 6. Limit contact with people             | 5            | 5                    |
| 7. Pleased with look of teeth            | 5            | 5                    |
| 8. Used medication to relieve pain       | 5            | 5                    |
| 9. Worried about teeth, gums or dentures | 5            | 3                    |
| 10. Self-conscious of teeth, gums or dentures | 5           | 5                    |
| 11. Uncomfortable eating in front of others | 5           | 5                    |
| 12. Sensitive to hot, cold or sweet foods | 4            | 5                    |
| Total                                    | 59           | 53                   |

Always – 1, Often – 2, Sometimes – 3, Seldom – 4, Never – 5. GOHAI General Oral Health Assessment Index
Table 2  Histopathological findings after preoperative chemotherapy

| Reference          | Number of cases | Sites          | Surgery            | Preoperative chemotherapy | Postoperative chemotherapy | Response                  | Prognosis |
|--------------------|-----------------|----------------|--------------------|---------------------------|----------------------------|---------------------------|-----------|
| Bertoni et al. (2005) [3] | 6               | Humerus, femur, tibia | Resection          | Details unknown           | None                       | Grade II                  | NED: 4     |
| Sheth et al. (1996) [4]  | 10              | Femur, tibia    | En bloc excision   | Intra-arterial cisplatin  | One of the following:     | Good response: 4          | NED: 5     |
|                     |                 |                |                    | (dose range, 120–160 mg/m²) | • high-dose methotrexate   | (with > 90% necrosis of the high-grade component). | DOD: 5     |
|                     |                 |                |                    | intravenously administered doxorubicin | • doxorubicin, dacarbazine | Poor response: 6         |           |
|                     |                 |                |                    | (dose range, 60–90 mg/m²), 4.2 cycles | • high-dose methotrexate, cisplatin | (with < 90% necrosis of the high-grade component) |           |
|                     |                 |                |                    | (range, 2–12 cycles)      | • high-dose methotrexate, doxorubicin, dacarbazine |                           |           |
|                     |                 |                |                    |                           | Doxorubicin, cisplatin     |                           |           |
| Futani et al. (2001) [11] | 1               | Fibula         | En bloc excision   | Intravenously administered high-dose methotrexate | None                      | 90% necrosis              | NED       |
|                     |                 |                |                    | (dose range, 9.5–11.4 g/m²), intra-arterial pirarubicin |                           |                           |           |
|                     |                 |                |                    | (dose range, 50–80 mg/m²), and dacarbazine |                           |                           |           |
|                     |                 |                |                    | (dose range, 400–600 mg/m²) three cycles |                           |                           |           |

DOD dead of disease, NED no evidence of disease

Abbreviations
CDDP: Cisplatin; c-POS: Conventional low-grade parosteal osteosarcoma; CT: Computed tomography; DPOS: Dedifferentiated parosteal osteosarcoma; IFO: Ifosfamide; MRI: Magnetic resonance imaging; NAC: Neoadjuvant chemotherapy; THP-ADM: Pirarubicin

Availability of data and materials
Please contact author for data requests.

Authors’ contributions
HK and HMi drafted and critically reviewed the manuscript. HK, HMi, KY, and MY performed the operation and did clinical follow-up of the patient. TS and MT contributed to data collection and literature search. KK, AS, and MH critically reviewed the manuscript from the histopathological perspective. HMo and TN conceived of the study and participated in its design. All authors read and approved the final manuscript.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Dentistry and Oral Surgery, Division of Oral and Maxillofacial Surgery, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. 2Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. 3Department of Diagnostic Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. 4Department of Pathology and Oncology, University of Occupational and Environmental Health, 1-1 Isiegaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. 5Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. 6Department of Orthopaedic Surgery, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Received: 26 June 2017 Accepted: 14 June 2018 Published online: 17 August 2018

References
1. Wold LE, Unni KK, Beabout JW, Sim FH, Dahlin DC. Dedifferentiated parosteal osteosarcoma. J Bone Joint Surg Am. 1984;66:53–9.
2. Okada K, Frassica FJ, Sim FH, Beabout JW, Bond JR, Unni KK. Parosteal osteosarcoma. A clinicopathological study. J Bone Joint Surg Am. 1994;76:636–78.
3. Bertoni F, Baccini P, Staals EL, Davidovitz P. Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer. 2005;103:2373–82.
4. Sheth DS, Yasko AW, Raymond AK, Ayala AG, Carrasco CH, Benjamin RS, et al. Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer. 1996;78:2136–45.
5. Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol. 2012;36:423–31.
6. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;Nov-Dec(153):106–20.
7. Tanaka K, Mizuazawa I, Fukuda H, Araki N, Chuman H, Takahashi M, et al. Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol. 2015;45:555–61.
8. Miyashita H, Asoda S, Horie N, Usuda S, Kato S, Muraoka W, et al. A titanium screw-retaining temporary denture on the raw surface muscular flap for the immediate maxillary reconstruction. J Oral Maxillofac Surg Med Pathol. 2016;28:8–12.
9. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–30.
10. Naito M, Suzukamo Y, Nakayama T, Hamajima N, Fukuhara S. Linguistic adaptation and validation of the General Oral Health Assessment Index (GOHAI) in an elderly Japanese population. J Public Health Dent. 2006;66:273–5.
11. Futani H, Okayama A, Maruo S, Kinosita G, Ishikura R. The role of imaging modalities in the diagnosis of primary dedifferentiated parosteal osteosarcoma. J Orthop Sci. 2001;6:290–4.
12. Donmez FY, Tuzun U, Basaran C, Tunaci M, Bilgic B, Acunas G. MRI findings in parosteal osteosarcoma: correlation with histopathology. Diagn Interv Radiol. 2008;14:142–52.

13. Takeuchi K, Morii T, Yabe H, Morioka H, Mukai M, Toyama Y. Dedifferentiated parosteal osteosarcoma with well-differentiated metastases. Skelet Radiol. 2006;35:778–82.